This article has been cited by
1Optimal usage of radium-223 in metastatic castration-resistant prostate cancer
Tai-Lung Cha,Tony Tong-Lin Wu,Nicholas John Vogelzang,Chao-Yuan Huang,Shu-Pin Huang,Chia-Chi Lin,Yen-Chuan Ou,See-Tong Pang,Daniel Heung-Yuan Shen,Wen-Jeng Wu,Wayne Yen-Hwa Chang
Journal of the Formosan Medical Association.2017;116(11)825
[DOI]
2The role of taxanes in prostate cancer: literature review
A. K. Norsov,S. A. Reva
Cancer Urology.2018;14(2)130
[DOI]
3Fluorescent dyes and probes for super-resolution microscopy of microtubules and tracheoles in living cells and tissues
Gražvydas Lukinavicius,Gyuzel Y. Mitronova,Sebastian Schnorrenberg,Alexey N. Butkevich,Hannah Barthel,Vladimir N. Belov,Stefan W. Hell
Chemical Science.2018;9(13)3324
[DOI]
4Navigating the evolving therapeutic landscape in advanced prostate cancer
E. David Crawford,Daniel Petrylak,Oliver Sartor
Urologic Oncology: Seminars and Original Investigations.2017;35(13)S1
[DOI]
5Personalized Herbal Medicine? A Roadmap for Convergence of Herbal and Precision Medicine Biomarker Innovations
Nicholas Ekow Thomford,Kevin Dzobo,Emile Chimusa,Kerstin Andrae-Marobela,Shadreck Chirikure,Ambroise Wonkam,Collet Dandara
OMICS: A Journal of Integrative Biology.2018;22(6)375
[DOI]
6Inhibitor of H3K27 demethylase JMJD3/UTX GSK-J4 is a potential therapeutic option for castration resistant prostate cancer
Viacheslav M. Morozov,Ying Li,Matthew M. Clowers,Alexander M. Ishov
Oncotarget.2017;8(37)62131
[DOI]
7Regulation of local steroidogenesis in the brain and in prostate cancer: Lessons learned from interdisciplinary collaboration
H. Bobby Fokidis,Hans H. Adomat,Geetanjali Kharmate,Elham Hosseini-Beheshti,Emma S. Guns,Kiran K. Soma
Frontiers in Neuroendocrinology.2015;36(37)108
[DOI]
8Mass spectrometry in the pharmacokinetic studies of anticancer natural products
Sara Crotti,Bianca Posocco,Elena Marangon,Donato Nitti,Giuseppe Toffoli,Marco Agostini
Mass Spectrometry Reviews.2017;36(2)213
[DOI]
9Cabazitaxel-conjugated nanoparticles for docetaxel-resistant and bone metastatic prostate cancer
Bryan Hoang,Mark J. Ernsting,Wei-Hsin Sophia Tang,Joseph Bteich,Elijus Undzys,Taira Kiyota,Shyh-Dar Li
Cancer Letters.2017;410(2)169
[DOI]
10SNPs associated with activity and toxicity of cabazitaxel in patients with advanced urothelial cell carcinoma
Ignacio Duran,Carlos Hagen,José Ángel Arranz,María Apellaniz-Ruiz,Begoña Pérez-Valderrama,Nuria Sala,Nuria Lainez,Xavier García-Del Muro,Esther Noguerón,Miguel Ángel Climent,Pablo Maroto,Albert Font,Jesús García-Donas,Enrique Gallardo,Pilar López-Criado,Aránzazu González Del Alba,María Isabel Sáez,Sergio Vázquez,Raquel Luque,Cristina Rodríguez-Antona
Pharmacogenomics.2016;17(5)463
[DOI]
11Enhancing the biocompatibility of rhodamine fluorescent probes by a neighbouring group effect
Jonas Bucevicius,Georgij Kostiuk,Ruta Gerasimaite,Tanja Gilat,Gražvydas Lukinavicius
Chemical Science.2020;11(28)7313
[DOI]
12Taxane anticancer agents: a patent perspective
Iwao Ojima,Brendan Lichtenthal,Siyeon Lee,Changwei Wang,Xin Wang
Expert Opinion on Therapeutic Patents.2016;26(1)1
[DOI]
13Lx2-32c, a novel semi-synthetic taxane, exerts antitumor activity against prostate cancer cells in vitro and in vivo
Guangyao Lv,Dengjun Sun,Jingwen Zhang,Xiaoxia Xie,Xiaoqiong Wu,Weishuo Fang,Jingwei Tian,Chunhong Yan,Hongbo Wang,Fenghua Fu
Acta Pharmaceutica Sinica B.2017;7(1)52
[DOI]
14Cell-Penetrating, Guanidinium-Rich Molecular Transporters for Overcoming Efflux-Mediated Multidrug Resistance
Jessica R. Vargas,Erika Geihe Stanzl,Nelson N. H. Teng,Paul A. Wender
Molecular Pharmaceutics.2014;11(8)2553
[DOI]
15Inhibit or Evade Multidrug Resistance P-Glycoprotein in Cancer Treatment
Deepali Waghray,Qinghai Zhang
Journal of Medicinal Chemistry.2018;61(12)5108
[DOI]
16Cabazitaxel exhibits more favorable molecular changes compared to other taxanes in androgen-independent prostate cancer cells
Ozge Cevik,Hilal Acidereli,Fatma Aysun Turut,Sahin Yildirim,Ceyda Acilan
Journal of Biochemical and Molecular Toxicology.2020;61(12)5108
[DOI]
17Formulation of Acid-Sensitive Micelles for Delivery of Cabazitaxel into Prostate Cancer Cells
Omer Aydin,Ibrahim Youssef,Yasemin Yuksel Durmaz,Gopinath Tiruchinapally,Mohamed E. H. ElSayed
Molecular Pharmaceutics.2016;13(4)1413
[DOI]
18Combination effect of therapies targeting the PI3K- and AR-signaling pathways in prostate cancer
Shalini Singh Yadav,Jinyi Li,Jennifer A. Stockert,James O’Connor,Bryan Herzog,Cordelia Elaiho,Matthew D. Galsky,Ashutosh Kumar Tewari,Kamlesh Kumar Yadav
Oncotarget.2016;7(46)76181
[DOI]
19Neuroprotective Approach of Anti-Cancer Microtubule Stabilizers Against Tauopathy Associated Dementia: Current Status of Clinical and Preclinical Findings
Pallavi Duggal,Sidharth Mehan
Journal of Alzheimer's Disease Reports.2019;3(1)179
[DOI]
20Inhibiting the NF-?B pathway enhances the antitumor effect of cabazitaxel by downregulating Bcl-2 in pancreatic cancer
Zequn Li,Zefeng Xuan,Jian Chen,Wenfeng Song,Shiyu Zhang,Cheng Jin,Mengqiao Zhou,Shusen Zheng,Penghong Song
International Journal of Oncology.2020;3(1)179
[DOI]
21APE1/Ref-1 redox-specific inhibition decreases survivin protein levels and induces cell cycle arrest in prostate cancer cells
David W. McIlwain,Melissa L. Fishel,Alexander Boos,Mark R. Kelley,Travis J. Jerde
Oncotarget.2018;9(13)10962
[DOI]
22UV spectroscopy and least square matching for high throughput discrimination of taxanes in commercial formulations and compounded bags
E. Jaccoulet,C. Boughanem,L. Auduteau,P. Prognon,E. Caudron
European Journal of Pharmaceutical Sciences.2018;123(13)143
[DOI]
23A nanoscale, biocompatible and amphiphilic prodrug of cabazitaxel with improved anticancer efficacy against 3D spheroids of prostate cancer cells
Ashok Kumar Jangid,Deep Pooja,Poonam Jain,Sri Vishnu Kiran Rompicharla,Shwathy Ramesan,Hitesh Kulhari
Materials Advances.2020;1(4)738
[DOI]
24Prostate Tumor Overexpressed-1 (PTOV1) promotes docetaxel-resistance and survival of castration resistant prostate cancer cells
Verónica Cánovas,Yolanda Puñal,Valentina Maggio,Enric Redondo,Mercedes Marín,Begoña Mellado,Mireia Olivan,Matilde Lleonart,Jacques Planas,Juan Morote,Rosanna Paciucci
Oncotarget.2017;8(35)59165
[DOI]
25Cabazitaxel and silibinin co-encapsulated cationic liposomes for CD44 targeted delivery: A new insight into nanomedicine based combinational chemotherapy for prostate cancer
Shaheen Mahira,Nagavendra Kommineni,Gulam Mohammed Husain,Wahid Khan
Biomedicine & Pharmacotherapy.2019;110(35)803
[DOI]
26

Preparation and Evaluation of Cabazitaxel-Loaded Bovine Serum Albumin Nanoparticles for Prostate Cancer

Zhong Wan,Fangyuan Xie,Liang Wang,Guoqing Zhang,Hai Zhang
International Journal of Nanomedicine.2020;Volume 15(35)5333
[DOI]
27Cabazitaxel overcomes cisplatin resistance in germ cell tumour cells
Mirjam Gerwing,Christine Jacobsen,Sergey Dyshlovoy,Jessica Hauschild,Tina Rohlfing,Christoph Oing,Simone Venz,Jan Oldenburg,Karin Oechsle,Carsten Bokemeyer,Gunhild von Amsberg,Friedemann Honecker
Journal of Cancer Research and Clinical Oncology.2016;142(9)1979
[DOI]
28Self-assembled Micelle Loading Cabazitaxel for therapy of Lung Cancer
Bo Zhuang,Liang Du,Hongxia Xu,Xuelian Xu,Cheng Wang,Yingfang Fan,Mengyi Cong,Jiaqi Yin,Hongxia Li,Huashi Guan
International Journal of Pharmaceutics.2016;499(1-2)146
[DOI]
29Early investigational tubulin inhibitors as novel cancer therapeutics
Kunal Nepali,Ritu Ojha,Hsueh-Yun Lee,Jing-Ping Liou
Expert Opinion on Investigational Drugs.2016;25(8)917
[DOI]
30Redox-Sensitive Citronellol–Cabazitaxel Conjugate: Maintained in Vitro Cytotoxicity and Self-Assembled as Multifunctional Nanomedicine
Peng Xue,Dan Liu,Jing Wang,Na Zhang,Jiahua Zhou,Lin Li,Weiling Guo,Mengchi Sun,Xiangfei Han,Yongjun Wang
Bioconjugate Chemistry.2016;27(5)1360
[DOI]
  Feedback 
  Subscribe